E. Alli

发表

A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.

W. Hait, J. Bash-Babula, D. Toppmeyer, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.

J. Ford, E. Alli, S. Casey, 2014, Cancer research.

Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells

E. Alli, L. McPherson, P. Lin, 2011, BMC pharmacology.

BRCA1: a movement toward cancer prevention

E. Alli, J. Ford, Elizabeth Alli, 2015, Molecular & cellular oncology.

Synergistic chemosensitivity of triple-negative breast cancer cell lines to PARP inhibition, gemcitabine and cisplatin

E. Alli, K. Hastak, J. Ford, 2010 .

BRCA1: Beyond double-strand break repair.

E. Alli, J. Ford, Elizabeth Alli, 2015, DNA repair.

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.

E. Alli, K. Hastak, J. Ford, 2010, Cancer research.

Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.

W. Hait, J. Bash-Babula, E. Alli, 2002, Cancer research.

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

E. Alli, J. Ford, Vandana B. Sharma, 2009, Cancer research.

Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma Cells

W. Hait, E. Alli, Jin-Ming Yang, 2007, Molecular Pharmacology.

Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53

W. Hait, E. Alli, J-M Yang, 2007, Oncogene.

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk

K. Jensen, J. Lipson, A. Kurian, 2013, Breast Cancer Research and Treatment.

Correcting errors in the BRCA1 warning system.

Deborah F. Kelly, Brian L. Gilmore, W. Dearnaley, 2019, DNA repair.

Silver nanoparticles selectively treat triple‐negative breast cancer cells without affecting non‐malignant breast epithelial cells in vitro and in vivo

E. Alli, Pierre-Alexandre Vidi, Ravi Singh, 2019, FASEB bioAdvances.

Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.

E. Alli, J. Ford, 2012, DNA repair.

Abstract #5642: Synergistic chemosensitivity of triple-negative breast cancer cell lines to a PARP inhibitor, cisplatin and gemcitabine

E. Alli, K. Hastak, J. Ford, 2009 .